SLC35C1 and cancer: Mapping the pan-cancer pharmacogenomic profiles of these FUTs and SLC35C1 revealed that their expression broadly correlated with resistance to multiple targeted therapies while their inhibitory cues (i.e. promoter methylation and GDP-Fuc binding site mutations) are widely associated with a drug-sensitive state.